Recondo et al. reported a patient harboring MET exon 14 skipping who experienced PD on crizotinib, and a resistance MET mutation of Y1230C was detected both in plasma and tumor tissue at the time of progression. This patient had a PR after switched to merestinib.55 These results supported that merestinib may provide a therapeutic option to patients with METex14. The first-in-human phase I study was to evaluate the safety and tolerability of merestinib including three types of tumor without NSCLC. Overall, 60 (32%) of the 186 patients enrolled in the study had a best response of SD, and recommended a dosing of merestinib at 120 mg once daily based on acceptable exposure and safety.56 A phase II study conducted by Awad et al. was to evaluate the safety and efficacy of merestinib in patients with advanced METex14 NSCLC or patients with advanced cancer with NTRK rearrangements (NCT02920996).54
Glesatinib Glesatinib (MGCD265; Mirati Therapeutics) is another orally bioavailable, type II, multi-targeted inhibitor with potential anti-tumor activity. Glesatinib binds to and inhibits the phosphorylation of several RTKs, including the MET receptor, the TEK/TIE-2 receptor, RON, SMO, and VEGFR types 1, 2, and 3. Preclinical studies showed that glesatinib resulted in a dose-dependent inhibition of cancer cell growth with an IC50 value of 80 nM on NSCLC H1299 cells.57 A patient with METex14 NSCLC showed response to glesatinib after relapsing to crizotinib, including a reduction in size of a MET Y1230H mutation-positive liver metastases and concurrent loss of detection of this mutation in plasma DNA. |
MET谷美替尼服用期间血酮血糖飙升居
去年11月底家人确诊肺腺癌IV期，右肺门及纵隔淋巴结转，心包，左侧肾上腺，脑转。经第
电场治疗癌症业余实现的探讨
2023.10.23 初版
2023.10.25 加一个PDF附件，删除个别错字
2023.10.27 增加功率放
请教一下基测无靶、免疫高表达后面的
治疗历程
1.治疗历程中的病情描述的变化都是基于第一次，变化于前一次的。
2.检查报告
第七次白紫后 没有明显疗效 请教下一
之前治疗经过：
去年10月左侧股骨放疗后，一直培美+贝伐维持一共用了5次
2024年开始培
肺腺癌egfr21-l858r突变，egfr扩增、
老爸21年3月发现肺腺癌晚期，双肺转移，纵隔淋巴结增大，取组织基因检测结果为egfr21-
显身卡
